FOXO4-DRI: promising mouse findings, context-dependent risks
Removing damaged cells helped some mice, but worsened disease in other experiments. FOXO4-DRI’s 2017 results opened a research path, not a proven anti-aging treatment. Cleara is developing distinct candidates for cancer and reports preclinical progress. The central question is which cells can be removed without harming the tissue they live in.
Longevitytech.fund investment
Cleara Biotech is a Longevitytech.fund portfolio company. We are proud of this investment in the development of targeted cancer medicines.
Evidence as of September 2026.
Shown: FOXO4-DRI removed selected senescent cells and improved some functions in mice; other experiments found no intended functional gain or worse disease. [1] [3] [4]
Not shown: a clinical benefit from FOXO4-DRI in people.
Would change the assessment: human results for a clearly identified candidate, with benefits and harms measured in a defined disease.
Removing an “old” cell can make things worse
In 2023 animal models of disease in the lung’s blood vessels, eliminating senescent cells—including with FOXO4-DRI—worsened outcomes. The finding is a warning against treating every senescent cell as disposable. It is not a result from treated patients. [4]
Senescent cells have stopped dividing after stress or damage but remain active. Some contribute to persistent inflammation; others help wound healing or prevent damaged cells from multiplying. A senolytic is a compound intended to remove selected senescent cells. Whether removal helps depends on the cell, tissue and disease. [1] [11]
What did FOXO4-DRI actually achieve?
The results support a research direction, with important differences between clearing cells and restoring tissue function.
Study | Finding | Verdict |
|---|---|---|
Cells and mice, 2017 | Some physical, fur and kidney measures improved | Animal benefit in tested settings [1] |
Human cartilage cells, 2021 | Fewer senescent cells; no improved cartilage formation | Cell clearance without intended functional gain [3] |
Lung-vessel disease models, 2023 | Disease development/progression worsened | Animal harm signal [4] |
Human scar cells/tissue, 2025 | Senescent-cell death in laboratory keloid models | Laboratory effect; patient benefit unknown [10] |
Cells and vascular-aging mouse models, 2026 | Favorable aortic and vessel-lining changes | Preclinical benefit; human outcomes unknown [5] |
The positive aortic results do not cancel the lung findings, because the tissues and conditions differ. Human cartilage or scar cells in a laboratory also do not establish a treatment for arthritis or scars in a person. [3] [4] [5] [10]
How is the peptide designed to work?
FOXO4-DRI interferes with an interaction between FOXO4 and p53, proteins that helped certain senescent cells survive in experiments. Disruption triggered programmed cell death, the cell’s controlled shutdown process. The peptide is an engineered short chain of protein building blocks; “DRI” refers to its chemical arrangement. [1]
A 2025 study refined how the compound binds to p53 and found contributions from more than one part of the peptide. Such work can improve drug design, but it does not identify a successful human treatment. [2]
Why is Cleara developing cancer candidates?
Cleara’s stated lead program targets cancer cells with impaired p53 signaling, rather than offering FOXO4-DRI as a general anti-aging treatment. Its candidates, including CL04183 and CL04177, have distinct identities and development programs. [6]
Cleara reports activity in cancer cells, three-dimensional tissue models and mice. Its business timeline says formal toxicology in rats and nonhuman primates was completed in 2025, alongside manufacturing work for a clinical-trial submission. Its public pipeline places the leading program in preclinical development. These are company-reported milestones, not published human efficacy results. [6] [7] [8]
A defined disease makes it possible to specify the target cells, intended benefit and acceptable risks. Progress in cancer would still leave healthy-aging use untested.
What are the risks and product-identity questions?
The central biological risk is removing cells that a tissue still needs. The lung-vessel results show why benefit cannot be assumed from the label “senolytic.” Human risks and long-term effects remain unresolved. [4]
An online vial labelled FOXO4-DRI is not shown to be equivalent to the material in a particular experiment, and its name does not connect it to Cleara’s candidates. Even a valid purity certificate would describe a sample, not establish human benefit or safety. [9]
What should we watch next?
The next meaningful milestones are a defined human study and transparent results, not another general claim about removing aging cells.
Clinical submission: evidence of a human-study application following Cleara’s reported 2025 toxicology and manufacturing work. [7]
Study design: an identified candidate, disease, eligibility criteria and safety plan when a human trial is publicly described. [8] [9]
Results: early safety and drug-behavior data, followed by evidence of patient benefit; the current preclinical stage supplies neither. [8] [9]
How Healthy Longevity Clinic experts evaluate the evidence
Healthy Longevity Clinic sees the central lesson of FOXO4-DRI in selectivity: removing the right cells may help, while removing cells a tissue still needs may harm. The favorable aortic findings and the adverse lung-vessel findings make that point concrete. Counting fewer senescent cells is not enough; tissue function must improve.
Our connection to Cleara through Longevitytech.fund makes this development path especially relevant to our coverage. We are proud of the investment. The research question is which defined candidate can help which patients, and what its human safety and benefit results show. Cleara's cancer program should be evaluated on that basis, rather than treated as proof of a general anti-aging intervention.
For a reader, this separates two legitimate interests: following a promising company and deciding whether a treatment is ready for personal use. A portfolio investment supports the work needed to answer the clinical questions; it does not supply their answers.
Three questions for a treatment discussion
Is the compound research FOXO4-DRI, CL04183 or something else?
Did removing the cells improve tissue function, or only reduce their number?
What human benefit and harm data exist for that exact candidate and disease?
Frequently asked questions
Does FOXO4-DRI reverse aging in people?
The studies discussed here do not demonstrate that. They concern cells and animal models, with outcomes that vary by tissue and disease. [1] [3] [4] [5]
Is Cleara developing the same product sold online?
Cleara identifies distinct drug candidates, including CL04183. An online product’s shared research name does not establish equivalence to those candidates or their manufacturing controls. [6] [7]
Are senolytics automatically beneficial?
No. Senescent cells can have useful roles, and removing them worsened outcomes in the cited lung-vessel models. Selectivity and tissue context are central to development. [4] [11]
What remains uncertain
The studies involve different tissues, disease models and compounds. Results in human cells are not treatment results in people. Company-reported toxicology and manufacturing progress do not establish human benefit or safety; online products cannot be assumed equivalent to research materials.
References
- Baar MP et al. Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging. Cell, 2017.
- Bourgeois B et al. The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI. Nature Communications, 2025.
- Huang Y et al. Senolytic peptide FOXO4-DRI selectively removes senescent cells from in vitro expanded human chondrocytes. Frontiers in Bioengineering and Biotechnology, 2021.
- Born E et al. Eliminating senescent cells can promote pulmonary hypertension development and progression. Circulation, 2023.
- Hu Z et al. FOXO4-DRI regulates endothelial cell senescence via the P53 signaling pathway. Frontiers in Bioengineering and Biotechnology, January 15, 2026.
- Cleara Biotech. Research focus and lead development candidates. Company source.
- Cleara Biotech. Business progress: investors, toxicology, and manufacturing milestones. Company source.
- Cleara Biotech. Pipeline. Company source.
- US Food and Drug Administration. The FDA’s drug review process: ensuring drugs are safe and effective.
- Kong YX et al. FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation. Communications Biology, 2025.
- National Institutes of Health. Senescent cells mapped in human body over the lifespan. July 1, 2026.
Disclosure
Cleara Biotech is a LongevityTech.fund portfolio company. This financial relationship is relevant to our coverage. Prepared with AI assistance.